ArticleClinical ophthalmology (Auckland, N.Z.)2026
MicroPulse Transscleral Cyclophotocoagulation for Early to Moderate Glaucoma: A Case Series of 11 Eyes with One-Year Follow-Up and Literature Review.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the efficacy and safety of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Chinese patients with early to moderate glaucoma over a one-year follow-up. Patients and Methods: This retrospective case series included 11 eyes of 11 consecutive Chinese patients with early to moderate glaucoma who underwent MP-TSCPC between November 2023 and March 2024. All patients were aged 18-80 years, had a baseline intraocular pressure (IOP) ≥ 21 mmHg, and completed at least 12 months of follow-up. MP-TSCPC was performed using an Iridex Cyclo G6 laser with standardized settings (2000 mW power, 31.3% duty cycle, 160 seconds total). Changes in IOP, the number of anti-glaucoma medications, best-corrected visual acuity (BCVA), surgical success rates, and complications were recorded. Results: At 12 months, mean IOP decreased significantly from 28.64±12.18 mmHg to 18.09±7.70 mmHg (P<0.05), and the mean number of anti-glaucoma medications was reduced from 3.27±0.91 to 1.64±1.00 (P<0.01). BCVA remained stable throughout follow-up. No severe complication occurred, transient mild anterior chamber inflammation resolved with treatment. Conclusion: Despite the small cohort size, MP-TSCPC demonstrates preliminary efficacy and good safety profile in IOP control in Chinese patients with early to moderate glaucoma, significantly lowering IOP and reducing medication burden without negatively impacting visual acuity or causing serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.